851069-97-1

Usage

Uses

Used in Pharmaceutical Industry:
6-[4-(TrifluoroMethoxy)phenyl]-3-pyridinecarbaldehyde is used as an intermediate in the synthesis of pharmaceuticals for its ability to modify the properties of biologically active molecules. Its trifluoromethoxy group enhances the lipophilicity and metabolic stability of the parent compound, making it a valuable building block in the development of new drugs.
Used in Agrochemical Industry:
6-[4-(TrifluoroMethoxy)phenyl]-3-pyridinecarbaldehyde is also used as an intermediate in the synthesis of agrochemicals, where its unique structure and properties can contribute to the development of effective and stable products for agricultural applications.
Used in Medicinal Chemistry and Drug Discovery:
6-[4-(TrifluoroMethoxy)phenyl]-3-pyridinecarbaldehyde is utilized in the field of medicinal chemistry and drug discovery due to its potential to improve the efficacy and pharmacokinetics of drug candidates. Its structural features make it a promising candidate for the design and synthesis of novel therapeutic agents.

Upstream product

• 149806-06-4 6-bromonicotinaldehyde 
• 139301-27-2 4-trifluoromethoxyphenylboronic acid 

Downstream Products

• 1361968-43-5 1-(6-(4-(trifluoromethoxy)phenyl)pyridin-3-yl)propan-1-ol 
• 1361967-16-9 7-methoxy-3-methyl-2-(6-(4-(trifluoromethoxy)phenyl)pyridin-3-yl)quinolin-4(1H)-one 
• 1361967-14-7 7-fluoro-3-methyl-2-(6-(4-(trifluoromethoxy)phenyl)pyridin-3-yl)quinolin-4(1H)-one 
• 1361967-11-4 C₂₃H₁₄F₆N₂O₂ 
• 1361968-51-5 1-(6-(4-(trifluoromethoxy)phenyl)pyridin-3-yl)propan-1-one 
• 1361967-08-9 C₂₃H₁₄F₆N₂O₃ 
• 1361967-06-7 6-methoxy-3-methyl-2-(6-(4-(trifluoromethoxy)phenyl)pyridin-3-yl)quinolin-4(1H)-one 
• 1361967-04-5 6-chloro-3-methyl-2-(6-(4-(trifluoromethoxy)phenyl)pyridin-3-yl)quinolin-4(1H)-one 
• 1361967-03-4 5-methoxy-3-methyl-2-(6-(4-(trifluoromethoxy)phenyl)pyridin-3-yl)quinolin-4(1H)-one 
• 1361967-00-1 SL-2-25 
• 1361967-34-1 C₂₂H₁₃ClF₄N₂O₂ 
• 1361967-32-9 C₂₂H₁₃ClF₄N₂O₂ 
• 1361968-37-7 3-methyl-2-(6-(4-(trifluoromethoxy)phenyl)pyridin-3-yl)quinolin-4-ylmorpholine-4-carboxylate 
• 1361968-36-6 3-methyl-2-(6-(4-(trifluoromethoxy)phenyl)pyridin-3-yl)quinolin-4-yl dihydrogen phosphate 

Relevant academic research and scientific papers

Antitubercular and Antiparasitic 2-Nitroimidazopyrazinones with Improved Potency and Solubility

Following the approval of delamanid and pretomanid as new drugs to treat drug-resistant tuberculosis, there is now a renewed interest in bicyclic nitroimidazole scaffolds as a source of therapeutics against infectious diseases. We recently described a nitroimidazopyrazinone bicyclic subclass with promising antitubercular and antiparasitic activity, prompting additional efforts to generate analogs with improved solubility and enhanced potency. The key pendant aryl substituent was modified by (i) introducing polar functionality to the methylene linker, (ii) replacing the terminal phenyl group with less lipophilic heterocycles, or (iii) generating extended biaryl side chains. Improved antitubercular and antitrypanosomal activity was observed with the biaryl side chains, with most analogs achieved 2- to 175-fold higher activity than the monoaryl parent compounds, with encouraging improvements in solubility when pyridyl groups were incorporated. This study has contributed to understanding the existing structure-activity relationship (SAR) of the nitroimidazopyrazinone scaffold against a panel of disease-causing organisms to support future lead optimization.

CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

2-Pyridylquinolone antimalarials with improved antimalarial activity and physicochemical properties

A series of 2-pyridylquinolones has been prepared in 5-7 steps and through lead optimisation, antimalarial activity as low as 12 nM against Plasmodium falciparum (Pf) has been achieved. Compared with previous analogues in this series, selected molecules h

Identification, design and biological evaluation of heterocyclic quinolones targeting plasmodium falciparum Type II NADH:Quinone oxidoreductase (PfNDH2)

Following a program undertaken to identify hit compounds against NADH:ubiquinone oxidoreductase (PfNDH2), a novel enzyme target within the malaria parasite Plasmodium falciparum, hit to lead optimization led to identification of CK-2-68, a molecule suitab

ANTIMALARIAL COMPOUNDS

The present invention relates to antimalarial compounds. More specifically, the present invention relates to novel substituted quinolone derivatives of formula (I) and related quinoline derivatives of formula (II) as defined herein that possess potent ant